HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. - Wikidata - wikimedia - TriplyDB

HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.

HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.

http://www.wikidata.org/entity/Q48017721

about

Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells.Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes.ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas.Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer.Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma.Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma.DNA methylation in hepatocellular carcinoma.Modern surgical techniques for management of soft tissue sarcomas involving the spine: outcomes and complications.Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells.Induction of Tissue Factor Pathway Inhibitor 2 by hCG Regulates Periovulatory Gene Expression and Plasmin Activity.Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion.Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells.Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism.Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

P2860

Q26781924-CDE08D45-C8DA-4ED2-BD44-F2C2AE902848 Q28364526-8D624F36-E0AF-4CC3-9957-962330C3F196 Q30909624-DA2D9F82-E947-4486-8730-ED5897AE701B Q30924151-45F10F70-5E12-4489-9750-A2024B387271 Q33241217-65089E5C-F4FA-45E5-8478-B2AC232DE1DC Q34079085-ED80E4D4-C4A3-4C89-B01C-C3968781D595 Q34113728-3E98AC29-6C10-4512-AAE4-D3C849CB4DA4 Q34467715-AA2BF8B3-AF84-466C-A36A-7D8AAC6A3405 Q34623032-7BDA9128-5A3B-498E-89BD-0169DA96AF30 Q34683461-9BE389C9-5608-4895-BAB0-47A861829BB9 Q35144899-B65B6694-2A04-4937-8782-299A6CAEAD8B Q35145167-514CDE6A-7C90-418D-A63E-064EAF7273F5 Q35858377-0AD0F72D-06A1-4298-AAA2-E1984E2DB925 Q36156149-B19E0772-A5CD-4A2C-8CFE-B5BF284E5952 Q36420282-3F7931FF-A733-40F8-BA50-FB35E2A59553 Q37113559-BAD29BC5-1F4C-4667-9AFE-3879DF954017 Q38270076-37398245-5ED5-4AF3-B581-9DC3DA123965 Q38350779-CAED7CCA-007F-43D3-B0C7-FF5CF0162871 Q39215224-8B773F7E-63D9-489C-84F5-F0375870757C Q40481644-EF6AA3A2-752B-4553-AABD-484222194161 Q40771328-D923568A-D428-410F-976E-D1CDE1BBDCCF Q41779392-EE48322E-DA25-45FF-A4C5-139750721FA6 Q42428677-B5135B86-631E-487D-9C4F-618DB7A9A7DE Q42670733-76DB3C03-25F5-404A-8D52-2AD5F59D88B0 Q42962995-1282DFA9-CA86-4976-802E-437568DA4CCE Q44526166-EBF1C9ED-83DF-441F-87A8-BF64F20DBBD9 Q44659688-B78AB809-BA15-435F-B692-40D454FB5811 Q47993444-CE774AAC-3D2A-4612-A84F-78985A6E0FDE

P2860

HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.

http://www.wikidata.org/entity/Q48017721

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh-hant

name

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@en

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@nl

type

label

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@en

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@nl

prefLabel

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@en

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@nl

P1433

Q48017721-27EB2350-99E5-4984-AE2E-C544CEDB6491

P1476

Q48017721-E5B55649-F257-402C-8928-BAE5019A875B

P2093

Q48017721-2D04159F-1138-446E-A76D-7DC25971EBB8

Q48017721-4518DFFD-EEEC-4855-BD74-09CD4C88C00C

Q48017721-4C4347CC-7BE5-4C32-84EA-0A98A4FA6636

Q48017721-54E6B79E-98F4-4D0E-AF30-7BA5719D0042

Q48017721-7582D046-760B-4B85-82C5-C3F76E3A6311

Q48017721-84FE8C44-9BD0-4EA6-8D2F-E1DDF13A0D92

Q48017721-9B4247EB-1718-4BBD-A0EB-05265F12EAD7

Q48017721-BF7A2159-C1AA-4DAC-9088-28AC56EAAAD0

P2860

Q48017721-0875CC3E-7C83-4BA7-BF64-F0ACA2F7DDB8

Q48017721-0DBDC46F-D017-4062-86A7-4B55DBE48444

Q48017721-104CF444-9269-4053-82E8-6E9C5AF01752

Q48017721-1AF31B5F-2E7D-4FCE-AC32-1680B826EB46

Q48017721-519495BC-F90D-4079-A9DD-B8E67C068D26

Q48017721-57852120-FA1E-4826-BDBB-09471D9968CC

Q48017721-5F5809A3-69D1-4D66-A792-E341C5A85AE3

Q48017721-6B442619-D44A-419F-ABD0-B150873E2B93

Q48017721-75869409-DBC3-489E-A631-607FE1B6FE94

Q48017721-8A3677FF-DA81-4FB2-87AA-2C5436D6D2A0

P304

Q48017721-D8A69CEE-207F-482C-ADCF-ADDA40E0FCD7

P31

Q48017721-986DB0DE-F568-40A6-92A6-E59864558A9C

P356

Q48017721-41D99E1F-AEE7-4D7D-8A60-6E578DB87B4E

P433

Q48017721-31C38505-4578-4AB1-B0CB-3251FE2A0FB4

P478

Q48017721-7370482A-9434-429B-927F-72A9FFECEDFB

P577

Q48017721-E7926B6E-D112-4778-B4C1-C303F171134C

P698

Q48017721-2F562B43-021C-4203-9BE0-FD625A06C6CC

P356

(SICI)1097-0215(19980529)76:5%3C749::AID-IJC21%3E3.0.CO;2-Y

P1433

International Journal of Cancer

P1476

HT-1080 fibrosarcoma cell matr ...... inhibitor TFPI-2/33 kDa MSPI.

@en

P2093

B Cook

http://www.w3.org/2001/XMLSchema#string

C N Rao

http://www.w3.org/2001/XMLSchema#string

D C Foster

http://www.w3.org/2001/XMLSchema#string

D T Woodley

http://www.w3.org/2001/XMLSchema#string

K Chilukuri

http://www.w3.org/2001/XMLSchema#string

M S Stack

http://www.w3.org/2001/XMLSchema#string

W Kisiel

http://www.w3.org/2001/XMLSchema#string

Y Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor

Purification and characterization of placental protein 5.

Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.

Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.

Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis.

Cloning of the cDNA encoding mouse PP5/TFPI-2 and mapping of the gene to chromosome 6.

Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2.

Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.

P304

749-756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

1998-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9610735

http://www.w3.org/2001/XMLSchema#string